JP2016508155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508155A5 JP2016508155A5 JP2015552096A JP2015552096A JP2016508155A5 JP 2016508155 A5 JP2016508155 A5 JP 2016508155A5 JP 2015552096 A JP2015552096 A JP 2015552096A JP 2015552096 A JP2015552096 A JP 2015552096A JP 2016508155 A5 JP2016508155 A5 JP 2016508155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid solution
- solution pharmaceutical
- weight
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000006104 solid solution Substances 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 150000003626 triacylglycerols Chemical class 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- -1 PEG500 Polymers 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims 1
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims 1
- DMCMOFCRZHRTKH-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOCCO.CCOCCOCCO DMCMOFCRZHRTKH-UHFFFAOYSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010044210 PPAR-beta Proteins 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 102000001424 Ryanodine receptors Human genes 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 229960003720 enoxolone Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752356P | 2013-01-14 | 2013-01-14 | |
| US61/752,356 | 2013-01-14 | ||
| US201361752309P | 2013-02-04 | 2013-02-04 | |
| US61/752,309 | 2013-02-04 | ||
| PCT/EP2014/050638 WO2014108574A1 (en) | 2013-01-14 | 2014-01-14 | Solid solution compositions and use in severe pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508155A JP2016508155A (ja) | 2016-03-17 |
| JP2016508155A5 true JP2016508155A5 (enExample) | 2017-02-16 |
| JP6378694B2 JP6378694B2 (ja) | 2018-08-22 |
Family
ID=50030251
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
| JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (6) | EP2943222B1 (enExample) |
| JP (6) | JP6389190B2 (enExample) |
| KR (6) | KR102235264B1 (enExample) |
| CN (4) | CN105007947B (enExample) |
| AU (4) | AU2014204734B2 (enExample) |
| BR (3) | BR112015015898B1 (enExample) |
| CA (3) | CA2897878A1 (enExample) |
| ES (5) | ES2829904T3 (enExample) |
| IL (5) | IL282123B (enExample) |
| MX (3) | MX379193B (enExample) |
| NZ (1) | NZ709486A (enExample) |
| PL (1) | PL3795141T3 (enExample) |
| RU (3) | RU2674982C2 (enExample) |
| SG (4) | SG11201505247TA (enExample) |
| WO (3) | WO2014108574A1 (enExample) |
| ZA (3) | ZA201505003B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| KR102235264B1 (ko) * | 2013-01-14 | 2021-04-02 | 인퍼스트 헬스케어 리미티드 | 고용체 조성물들 및 심각한 통증에서의 이들의 용도 |
| MX387217B (es) * | 2015-08-07 | 2025-03-18 | Infirst Healthcare Ltd | Composiciones de solución sólida para aines. |
| US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| KR102701244B1 (ko) | 2017-10-23 | 2024-09-02 | 에피트래커, 인코포레이티드 | 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도 |
| AU2019271067B2 (en) * | 2018-05-16 | 2023-08-03 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to aging |
| AU2019274431B2 (en) | 2018-05-23 | 2025-03-13 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| CN108653273A (zh) * | 2018-07-13 | 2018-10-16 | 昆明医科大学第附属医院 | 青蒿素类化合物作为制备治疗贝赫切特病药物的应用 |
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP7404382B2 (ja) | 2019-03-04 | 2023-12-25 | エピトラッカー インコーポレイテッド | 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用 |
| CN110251549B (zh) * | 2019-06-24 | 2021-12-03 | 浙江省肿瘤医院 | 淫羊藿总黄酮提取物在制备防治桥本甲状腺炎的药物中的应用 |
| WO2020259670A1 (zh) * | 2019-06-28 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | 一种缓释脂质组合物及其制备方法 |
| CA3109520C (en) * | 2019-07-21 | 2021-09-07 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| EP4100029A4 (en) * | 2020-02-03 | 2024-03-06 | Curemast, Inc. | COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OF MASTITIS |
| RU2752764C1 (ru) * | 2020-12-14 | 2021-08-03 | Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") | Фармацевтическая композиция, обладающая противовоспалительным действием |
| CA3212583A1 (en) | 2021-03-27 | 2022-10-06 | Daniel Gooding | Compositions having improved bioavailability of therapeutics |
| EP4426130A1 (en) | 2021-11-03 | 2024-09-11 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| CN114601843A (zh) * | 2022-03-22 | 2022-06-10 | 重庆医科大学附属第一医院 | 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途 |
| GB202208911D0 (en) * | 2022-06-17 | 2022-08-10 | Ravan Bio Limtied | Treatments |
| AU2023321655A1 (en) | 2022-08-12 | 2025-02-13 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
| GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| ATE265847T1 (de) * | 1997-07-29 | 2004-05-15 | Upjohn Co | Selbstemulgierbare formulierung enthaltend lipophile verbindungen |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US8663692B1 (en) * | 1999-05-07 | 2014-03-04 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| BR0010354A (pt) * | 1999-05-07 | 2002-03-05 | Pharmasol Gmbh | Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção |
| CA2377301C (en) * | 1999-06-14 | 2009-05-12 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| AU7984200A (en) * | 1999-09-21 | 2001-04-24 | Skyepharma Canada Inc. | Surface modified particulate compositions of biologically active substances |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
| JP2002284705A (ja) * | 2001-01-19 | 2002-10-03 | Shiseido Co Ltd | 刺激緩和剤 |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| JP2007500691A (ja) * | 2003-07-31 | 2007-01-18 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗炎症剤の分散性製剤 |
| CA2540984C (en) * | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
| ZA200604250B (en) * | 2003-11-13 | 2007-11-28 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| KR20060125824A (ko) * | 2003-12-01 | 2006-12-06 | 라이프사이클 파마 에이/에스 | 레르카니디핀을 포함한 약학적 조성물 |
| WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| CA2560613C (en) * | 2004-03-22 | 2015-11-24 | Solvay Pharmaceuticals Gmbh | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| BRPI0518484A2 (pt) * | 2004-11-24 | 2008-11-18 | Merck & Co Inc | composiÇço, cÁpsula, e, processo para preparar a mesma |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| EA012882B1 (ru) * | 2005-04-28 | 2009-12-30 | ДСМ АйПи ЭССЕТС Б.В. | Фармацевтические лекарственные формы, содержащие липидную фазу |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| RU2353349C2 (ru) * | 2007-04-18 | 2009-04-27 | Общество с ограниченной ответственностью "Фармацевтические технологии" | Средство для лечения болезней суставов |
| CN101129335B (zh) * | 2007-07-17 | 2010-09-22 | 浙江大学 | 一种纳米结构脂质载体给药系统的用途 |
| US8461183B2 (en) | 2008-05-26 | 2013-06-11 | Genfit | PPAR agonist compounds, preparation and uses |
| GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
| MX346224B (es) * | 2011-02-04 | 2017-03-10 | Biocopea Ltd | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. |
| EP2688560A2 (en) * | 2011-03-24 | 2014-01-29 | Leo Pharma A/S | A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| CN102793628B (zh) * | 2012-08-23 | 2014-07-02 | 东华大学 | 用于化妆品的液-固混合脂质纳米缓释系统及其制备方法 |
| KR102235264B1 (ko) * | 2013-01-14 | 2021-04-02 | 인퍼스트 헬스케어 리미티드 | 고용체 조성물들 및 심각한 통증에서의 이들의 용도 |
-
2014
- 2014-01-14 KR KR1020157021076A patent/KR102235264B1/ko active Active
- 2014-01-14 EP EP14701930.1A patent/EP2943222B1/en active Active
- 2014-01-14 CA CA2897878A patent/CA2897878A1/en not_active Abandoned
- 2014-01-14 SG SG11201505247TA patent/SG11201505247TA/en unknown
- 2014-01-14 ES ES14701930T patent/ES2829904T3/es active Active
- 2014-01-14 AU AU2014204734A patent/AU2014204734B2/en active Active
- 2014-01-14 CA CA2898000A patent/CA2898000A1/en not_active Abandoned
- 2014-01-14 JP JP2015552095A patent/JP6389190B2/ja active Active
- 2014-01-14 ES ES19188174T patent/ES2875824T3/es active Active
- 2014-01-14 PL PL20192758.9T patent/PL3795141T3/pl unknown
- 2014-01-14 WO PCT/EP2014/050638 patent/WO2014108574A1/en not_active Ceased
- 2014-01-14 EP EP20192758.9A patent/EP3795141B1/en active Active
- 2014-01-14 MX MX2015009105A patent/MX379193B/es unknown
- 2014-01-14 JP JP2015552096A patent/JP6378694B2/ja active Active
- 2014-01-14 NZ NZ709486A patent/NZ709486A/en unknown
- 2014-01-14 KR KR1020217009229A patent/KR102338569B1/ko active Active
- 2014-01-14 SG SG11201505249VA patent/SG11201505249VA/en unknown
- 2014-01-14 CN CN201480006940.XA patent/CN105007947B/zh active Active
- 2014-01-14 EP EP14702460.8A patent/EP2925367B1/en active Active
- 2014-01-14 WO PCT/EP2014/050636 patent/WO2014108572A1/en not_active Ceased
- 2014-01-14 CN CN201910070081.5A patent/CN109549927B/zh active Active
- 2014-01-14 MX MX2015009104A patent/MX377340B/es active IP Right Grant
- 2014-01-14 KR KR1020157021075A patent/KR20150125648A/ko not_active Ceased
- 2014-01-14 CA CA2897884A patent/CA2897884C/en active Active
- 2014-01-14 SG SG10201704472QA patent/SG10201704472QA/en unknown
- 2014-01-14 BR BR112015015898-6A patent/BR112015015898B1/pt active IP Right Grant
- 2014-01-14 BR BR112015015891-9A patent/BR112015015891B1/pt active IP Right Grant
- 2014-01-14 ES ES20192758T patent/ES3041421T3/es active Active
- 2014-01-14 KR KR1020237002149A patent/KR20230017914A/ko not_active Ceased
- 2014-01-14 WO PCT/EP2014/050637 patent/WO2014108573A1/en not_active Ceased
- 2014-01-14 EP EP14703279.1A patent/EP2943223B1/en active Active
- 2014-01-14 KR KR1020157021073A patent/KR102252574B1/ko active Active
- 2014-01-14 IL IL282123A patent/IL282123B/en unknown
- 2014-01-14 AU AU2014204737A patent/AU2014204737B2/en active Active
- 2014-01-14 RU RU2015134143A patent/RU2674982C2/ru active IP Right Revival
- 2014-01-14 ES ES14702460T patent/ES2763352T3/es active Active
- 2014-01-14 RU RU2015134141A patent/RU2675241C2/ru active IP Right Revival
- 2014-01-14 IL IL295091A patent/IL295091B2/en unknown
- 2014-01-14 KR KR1020217040230A patent/KR102491426B1/ko active Active
- 2014-01-14 CN CN201480006298.5A patent/CN104981253B/zh active Active
- 2014-01-14 RU RU2015134142A patent/RU2667977C2/ru active IP Right Revival
- 2014-01-14 BR BR112015015858-7A patent/BR112015015858B1/pt active IP Right Grant
- 2014-01-14 SG SG11201505241WA patent/SG11201505241WA/en unknown
- 2014-01-14 JP JP2015552094A patent/JP6505607B2/ja active Active
- 2014-01-14 MX MX2015009106A patent/MX377877B/es unknown
- 2014-01-14 ES ES14703279T patent/ES2830033T3/es active Active
- 2014-01-14 AU AU2014204735A patent/AU2014204735B2/en active Active
- 2014-01-14 EP EP19188174.7A patent/EP3578172B1/en active Active
- 2014-01-14 CN CN201480006216.7A patent/CN104968368B/zh active Active
- 2014-01-14 EP EP21164383.8A patent/EP3858335A1/en active Pending
-
2015
- 2015-07-13 ZA ZA2015/05003A patent/ZA201505003B/en unknown
- 2015-07-13 ZA ZA2015/05002A patent/ZA201505002B/en unknown
- 2015-07-13 ZA ZA2015/05004A patent/ZA201505004B/en unknown
- 2015-07-14 IL IL239924A patent/IL239924A0/en unknown
- 2015-07-14 IL IL239923A patent/IL239923A0/en unknown
- 2015-07-14 IL IL239922A patent/IL239922B/en active IP Right Grant
-
2016
- 2016-11-11 AU AU2016256804A patent/AU2016256804B2/en active Active
-
2019
- 2019-03-27 JP JP2019061720A patent/JP2019116498A/ja active Pending
-
2021
- 2021-08-27 JP JP2021139210A patent/JP7250865B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045431A patent/JP7748411B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508155A5 (enExample) | ||
| JP2016504403A5 (enExample) | ||
| JP2016505625A5 (enExample) | ||
| RU2015134141A (ru) | Композиции твердых растворов и их применение при хроническом воспалении | |
| AR122743A2 (es) | Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| JP2016504401A5 (enExample) | ||
| AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
| HRP20201043T1 (hr) | Spojevi 4-amino-imidazokinolina | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HN2012001037A (es) | Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos | |
| DOP2014000016A (es) | Indazoles novedosos inhibidores de janus quinasa | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| CU24355B1 (es) | Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina | |
| JP2014509655A5 (enExample) | ||
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| JP2016511753A5 (enExample) |